FT-895 | HDAC inhibitor | CAS#2225728-57-2

MedKoo Cat#: 127584 | Name: FT-895

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FT-895, also known as HDTK 070, is an HDAC inhibitor

Chemical Structure

FT-895

CAS#2225728-57-2

Theoretical Analysis

MedKoo Cat#: 127584

Name: FT-895

CAS#: 2225728-57-2

Chemical Formula: C16H15F3N4O2

Exact Mass: 352.1147

Molecular Weight: 352.32

Elemental Analysis: C, 54.55; H, 4.29; F, 16.18; N, 15.90; O, 9.08

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

FT-895; FT 895; FT895; HDTK 070; HDTK-070; HDTK070;

IUPAC/Chemical Name

N-hydroxy-1,1-dimethyl-2-(5-(trifluoromethyl)pyrazin-2-yl)isoindoline-4-carboxamide

InChi Key

XCLPBILTRRWOIL-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H15F3N4O2/c1-15(2)11-5-3-4-9(14(24)22-25)10(11)8-23(15)13-7-20-12(6-21-13)16(17,18)19/h3-7,25H,8H2,1-2H3,(H,22,24)

SMILES Code

CC1(C2=CC=CC(=C2CN1C3=NC=C(N=C3)C(F)(F)F)C(=O)NO)C

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 352.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Huang PY, Shih IA, Liao YC, You HL, Lee MJ. FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. Int J Mol Sci. 2023 Dec 24;25(1):277. doi: 10.3390/ijms25010277. PMID: 38203448; PMCID: PMC10779378. 2: Xie H, Yang E, Wang C, Peng C, Ji L. Targeting HDAC11 activity by FT895 restricts EV71 replication. Virus Res. 2023 Jun;330:199108. doi: 10.1016/j.virusres.2023.199108. Epub 2023 Apr 15. PMID: 37024058; PMCID: PMC10194106. 3: Robinson EL, Bagchi RA, Major JL, Bergman BC, Matsuda JL, McKinsey TA. HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance. J Clin Invest. 2023 Oct 2;133(19):e168192. doi: 10.1172/JCI168192. PMID: 37607030; PMCID: PMC10541202. 4: Robinson EL, Bagchi RA, Major JL, Bergman BC, Madsuda JL, McKinsey TA. HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance. bioRxiv [Preprint]. 2023 Mar 30:2023.03.29.534830. doi: 10.1101/2023.03.29.534830. Update in: J Clin Invest. 2023 Oct 2;133(19):e168192. doi: 10.1172/JCI168192. PMID: 37034582; PMCID: PMC10081236. 5: Wu H, Yin X, Zhao X, Wu Z, Xiao Y, Di Q, Sun P, Tang H, Quan J, Chen W. HDAC11 negatively regulates antifungal immunity by inhibiting Nos2 expression via binding with transcriptional repressor STAT3. Redox Biol. 2022 Oct;56:102461. doi: 10.1016/j.redox.2022.102461. Epub 2022 Sep 3. PMID: 36087429; PMCID: PMC9465110. 6: Huang PY, Shih IA, Liao YC, You HL, Lee MJ. A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway. Am J Cancer Res. 2022 Feb 15;12(2):873-892. PMID: 35261809; PMCID: PMC8899988. 7: Baselious F, Robaa D, Sippl W. Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case study. Comput Biol Med. 2023 Dec;167:107700. doi: 10.1016/j.compbiomed.2023.107700. Epub 2023 Nov 10. PMID: 37972533. 8: Martin MW, Lee JY, Lancia DR Jr, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X. Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett. 2018 Jul 1;28(12):2143-2147. doi: 10.1016/j.bmcl.2018.05.021. Epub 2018 May 9. PMID: 29776742. 9: Baselious F, Hilscher S, Hagemann S, Tripathee S, Robaa D, Barinka C, Hüttelmaier S, Schutkowski M, Sippl W. Utilization of an optimized AlphaFold protein model for structure-based design of a selective HDAC11 inhibitor with anti-neuroblastoma activity. Arch Pharm (Weinheim). 2024 Jul 12:e2400486. doi: 10.1002/ardp.202400486. Epub ahead of print. PMID: 38996352. 10: Byeon HE, Choi SE, Kim Y, Choi S, Lee SJ, Kim DH, Mo JS, Jeon JY. HDAC11 Regulates Palmitate-induced NLRP3 Inflammasome Activation by Inducing YAP Expression in THP-1 Cells and PBMCs. Endocrinology. 2024 Jan 16;165(3):bqae011. doi: 10.1210/endocr/bqae011. PMID: 38366363.